DexCom - DXCM Stock Forecast, Price & News

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Stock Performance

DXCM Stock traded up $1.59 during mid-day trading on Friday, hitting $89.83. 1,914,913 shares of the company were exchanged, compared to its average volume of 3,152,051. The business has a 50 day simple moving average of $78.92 and a 200-day simple moving average of $94.89. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $35.27 billion, a PE ratio of 187.15, a price-to-earnings-growth ratio of 3.53 and a beta of 1.03. DexCom has a 1-year low of $66.89 and a 1-year high of $164.86.

DexCom (NASDAQ:DXCM - Get Rating) last issued its quarterly earnings data on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $696.20 million for the quarter, compared to analyst estimates of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The company's revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business earned $0.19 earnings per share. On average, equities analysts forecast that DexCom will post 0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DXCM. Sanford C. Bernstein began coverage on shares of DexCom in a research note on Friday, July 15th. They set an "outperform" rating and a $105.00 price objective for the company. Cowen restated a "buy" rating and set a $85.00 price objective on shares of DexCom in a research note on Friday, July 29th. SVB Leerink reduced their price objective on shares of DexCom from $141.25 to $125.00 in a research note on Friday, April 29th. Wells Fargo & Company reduced their price objective on shares of DexCom from $144.00 to $102.00 in a research note on Friday, July 29th. Finally, Robert W. Baird cut their target price on shares of DexCom from $115.00 to $97.00 in a research note on Friday, July 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average target price of $115.23.

Insider Transactions at DexCom

In other news, Director Steven Robert Pacelli sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $72.55, for a total transaction of $72,550.00. Following the transaction, the director now directly owns 139,700 shares of the company's stock, valued at $10,135,235. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Steven Robert Pacelli sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $72.55, for a total transaction of $72,550.00. Following the transaction, the director now directly owns 139,700 shares of the company's stock, valued at $10,135,235. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jereme M. Sylvain sold 600 shares of the firm's stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $301.57, for a total transaction of $180,942.00. Following the transaction, the chief financial officer now directly owns 17,408 shares in the company, valued at $5,249,730.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,850 shares of company stock valued at $410,645. 0.41% of the stock is currently owned by company insiders.